Contact us

CDMO Directory
Directory for Contract Manufacturing

Find the Best Partners with Our Comprehensive CDMO Directory

Showing 203 facilities
SENN Chemicals | R&D and Kilo Lab | Dielsdorf, Switzerland
Switzerland

SENN Chemicals | R&D and Kilo Lab | Dielsdorf, Switzerland

Senn Chemicals

Swiss peptide and peptide intermediates R&D site with SPPS, LPPS, hybrid synthesis, kilo lab scale up, purification and analytics.

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

CATEGORY / PRODUCT: COSMETICS, CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING

BATCH SIZE: Small

SENN Chemicals | Small Scale GMP Lab | Dielsdorf, Switzerland
Switzerland

SENN Chemicals | Small Scale GMP Lab | Dielsdorf, Switzerland

Senn Chemicals

Small scale GMP peptide and organic synthesis lab for clinical, niche and high value projects requiring flexible cGMP production.

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING

BATCH SIZE: Small

SENN Chemicals | GMP Production | Dielsdorf, Switzerland
Switzerland

SENN Chemicals | GMP Production | Dielsdorf, Switzerland

Senn Chemicals

Swiss cGMP production site for LPPS, SPPS and hybrid peptide manufacturing from pilot to early commercial scale.

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

BATCH SIZE: Large, Medium

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING

SENN India | Non-GMP Plant | Hyderabad, India
India

SENN India | Non-GMP Plant | Hyderabad, India

Senn Chemicals

Large scale non GMP manufacturing site for peptide intermediates, organic synthesis, LPPS operations and scale up production.

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: APAC

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: COSMETICS, CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING

SENN India | R&D Lab | Hyderabad, India
India

SENN India | R&D Lab | Hyderabad, India

Senn Chemicals

R&D centre for peptide and organic chemistry with SPPS, purification, lyophilisation, analytics and particle engineering support.

SERVICES: Logistics, Development services, Analytical / QC services, Quality Assurance services, Packaging

REGION: APAC

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING

BATCH SIZE: Small

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)
Spain

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)

LABORATORIO REIG JOFRE SA

Betalactam antibiotics (FDF) development and manufacturing state-of-the-art facilities.

MARKETS: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europe, North America

COMPLIANCE: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Laboratorios Grifols | Barcelona Plant
Spain

Laboratorios Grifols | Barcelona Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags and vials.

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

White Raven - Legiapark
Belgium

White Raven - Legiapark

White Raven

Fill and finish site dedicated to GMP Formulation and the Aseptic filling of Sterile Liquid Injectables.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU)

REGION: Europe

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Manufacturing services, Packaging

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)
Spain

Laboratorio REIG JOFRE, SA (BARCELONA PLANT)

LABORATORIO REIG JOFRE SA

Injectable (lyo and liquid) and Liquid manufacturing facilities.

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MHRA (UK), INVIMA (Colombia), MFDS (South Korea), TGA (Australia)

REGION: Europe

BATCH SIZE: Large, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), ECOVADIS, INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Sylentis
Spain

Sylentis

Sylentis

Oligonucleotide manufacturer.

COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)

MARKETS: EMA (EU), FDA (USA)

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: OLIGONUCLEOTIDES

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

VIVEbiotech
Spain

VIVEbiotech

VIVEbiotech

Your leading GMP-certified CDMO exclusively dedicated to the production of lentiviral vectors.

MARKETS: EMA (EU), FDA (USA), MHRA (UK)

REGION: Europe

COMPLIANCE: FDA (cGMP), French Service-Public (CIR), EMA (EU GMP), MHRA (UK GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

CATEGORY / PRODUCT: BIOLOGICS

Viswa Laboratories Pvt Ltd
India

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, APIs, Intermediates and specialty chemicals.

MARKETS: EMA (EU), NMPA (China), ANVISA (Brazil), Russian Health Authorities, CDSCO (India)

REGION: APAC

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (R) Respiratory system

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

COMPLIANCE: World Health Organization (GMP / HACCP)

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+112 more facilities

Create free account

In the dynamic landscape of pharmaceutical contract development and manufacturing, partnering with the right Contract Development and Manufacturing Organization (CDMO) is crucial for success. A comprehensive CDMO directory serves as an invaluable resource, guiding pharmaceutical companies to find partners that align with their specific needs and objectives.

Understanding CDMOs and Their Importance

CDMOs specialize in providing comprehensive services ranging from drug development to manufacturing, enabling pharmaceutical companies to focus on core competencies such as research and marketing. By outsourcing these critical processes, companies can accelerate time-to-market, optimize resources, and maintain flexibility in production scaling.

The Role of a CDMO Directory

A well-curated CDMO directory simplifies the process of identifying and connecting with suitable partners. It offers detailed profiles of various organizations, highlighting their capabilities, areas of expertise, and compliance standards. This transparency allows pharmaceutical companies to make informed decisions, ensuring that their chosen CDMO can meet regulatory requirements and project demands.

Key Features of an Effective CDMO Directory

Offering broad coverage through Comprehensive Listings: An extensive database that includes CDMOs from various regions and specialties ensures that companies can find partners that meet their specific criteria.

Evaluating provider capabilities via Detailed Profiles: Information on each CDMO's services, technological capabilities, certifications, and past projects provides a clear understanding of their expertise.

Targeting specific parameters with Search and Filter Options: Advanced search functionalities allow users to filter CDMOs based on parameters such as location, service offerings, and compliance with specific regulatory bodies.

Verifying performance history through User Reviews and Ratings: Incorporating feedback from previous clients offers insights into the CDMO's reliability, quality of service, and adherence to timelines.

Ensuring current industry accuracy via Up-to-Date Information: Regular updates ensure that the directory reflects the current status of each CDMO, including any new certifications, expansions, or changes in services.

Benefits of Using a CDMO Directory

Accelerating partner selection through Efficiency: Streamlines the partner selection process by providing all necessary information in one place.

Verifying compliance standards for Risk Mitigation: Access to compliance and certification details helps in selecting CDMOs that meet regulatory standards, reducing the risk of non-compliance.

Optimizing budget allocation by remaining Cost-Effective: By identifying CDMOs that offer competitive pricing and services tailored to specific needs, companies can optimize their budgets.

Fostering industry collaboration with Networking Opportunities: Facilitates connections within the industry, potentially leading to collaborations beyond manufacturing, such as research partnerships.

MAI CDMO's CDMO Directory Bridges the Gap in Pharmaceutical Outsourcing

One notable platform in this space is MAI CDMO, a software development company dedicated to fostering a collaborative ecosystem within the pharmaceutical industry. By bridging the gap between pharmaceutical companies and CMO/CDMOs, MAI CDMO ensures optimal resource allocation throughout the development process. This collaborative approach empowers partners to achieve their goals with greater efficiency and focus on innovation.

Navigating the CDMO Landscape

The pharmaceutical industry is continually evolving, with new technologies and methodologies emerging regularly. A reliable CDMO directory keeps pace with these changes, offering updated information on CDMOs that adopt innovative approaches, such as continuous manufacturing, single-use technologies, and advanced analytics.

Global Reach and Local Expertise

While global CDMOs offer extensive resources and capabilities, regional CDMOs provide local expertise and a better understanding of specific market dynamics. A comprehensive CDMO directory includes both, allowing companies to choose partners that best fit their strategic goals, whether it's entering a new market or leveraging specialized local knowledge.

Ensuring Quality and Compliance

Quality assurance is paramount in pharmaceutical manufacturing. A CDMO directory that provides information on quality metrics, inspection histories, and compliance records enables companies to select partners committed to maintaining high standards. This focus on quality not only ensures patient safety but also protects the company's reputation.

Future Trends in CDMO Partnerships

As the pharmaceutical industry embraces personalized medicine, biologics, and gene therapies, the role of CDMOs is expanding. Directories that highlight CDMOs with capabilities in these cutting-edge areas become essential tools for companies looking to innovate and stay competitive.

Conclusion

A quality CDMO directory is more than just a list; it's a strategic resource that empowers pharmaceutical companies to find the right partners efficiently. By providing detailed, up-to-date information, such directories facilitate collaborations that drive innovation, ensure compliance, and ultimately lead to the successful development and delivery of life-saving therapies.

Leveraging a platform like MAI CDMO can significantly enhance the outsourcing process, fostering a collaborative environment that benefits all stakeholders in the pharmaceutical industry. As the landscape continues to evolve, these directories will play a pivotal role in shaping the future of pharmaceutical development and manufacturing.